The funding announced today is part of $3 billion that will be invested in cancer research projects during the next 10 years.

The Austin-based organization awarded 66 projects funding, which were chosen from about 900 proposals. A team of 100 experts reviewed applications and chose projects that study causes and treatments for brain, breast, blood, cervical, colon, liver, lung, ovarian, and prostate cancer.

At the same time, the institute awarded the University of Texas Health Science Center in San Antonio the second CPRIT Scholar in Cancer Research. The facility will use the donation to recruit new staff.

Texas voters passed a constitutional amendment that created the organization in 2007. The state garnered $3 billion in bonds for research that aims to expedite innovation and commercialization in cancer research.

The University of Texas was among the winners.

Lloyd Webber, 61, said in a health diary published on his website that he noticed the first symptoms of his cancer last summer and underwent an operation to remove his prostate gland after a biopsy came back positive.

He was told the cancer had been caught early and the treatment was successful, but he then battled an underlying e-coli infection that had been there all along.

“If that infection had been found and cured, I could have been blissfully unaware that I had a cancerous tumor that was on the verge of breaking loose around the rest of my body. I could have thought that my frequent peeing was due to a weak bladder. I have been bloody lucky,” wrote Lloyd Webber.

“I say to every red-blooded male, if you do begin to have a problem down under, however embarrassing, go to your GP at once. Even if you don’t have any symptoms, if you are over 50 get regular PSA (prostate specific antigen) tests.”

Lloyd Webber, the composer behind hit musicals including “Jesus Christ Superstar,” “Cats” and “Starlight Express,” is staging a sequel to “The Phantom of the Opera” called “Love Never Dies” that is due to open in London in March this year.

He has also just kicked off a search for Dorothy to star in his West End production of “The Wizard of Oz” with his search to be the topic of a BBC television talent show.

Interview with Andrew Lloyd Webber

Harvard researchers are finding an intriguing link between coffee and the prevention of an aggressive type of prostate cancer.

Prostate cancer kills 27,000 men annually. So this research comparing the history of thousands and thousands of men raises the possibility of a simple and effective prevention in this deadly disease.

The researchers discovered that men who drank six or more cups of coffee a day had a 60 percent lower risk developing the advanced form of the disease when compared to men who drank no coffee at all.

Even men who drank just one to three cups are showed a lower risk, about 20 percent, of developing the aggressive cancer.

Prostate cancer specialist Dr. Ihor Sawczuk, of Hackensack University Medical Center, says the researchers were not exactly sure what it is about the coffee that might affect the cancers. But he says it’s too early to recommend boosting coffee drinking to men, although one cup of coffee might be helpful.

“I think those that don’t drink coffee should consider perhaps a cup a day may help build up their immune system,” he said. “I think what we need to remember is there may be more to this story.”

And finding out more details will be the next job for researchers. Because one study is not enough for scientists, the findings will need to be confirmed.

But if coffee helps prevention, it’s a bonus for those who already drink it and a simple benefit for those who don’t.

Prostate cancer survivor Richard Williamson has made some already-proven lifestyle changes for his recovery. He’s lost 25 pounds, walks two miles daily and, because he doesn’t eat enough fruits and vegetables, now frequents a health food store near his home to get his vegetables in a drink he likes.

“I do my walk and then I stop there,” he said. “I do that three or four times a week.”

Other proven prevention habits include:

“Decrease the total amount of fat, taking good fat, for example, the omega-3,” Dr. Sawczuk said. “Tomatoes have lycopene, especially the skin of tomatoes. These are good substancse to ingest. Soy products, apples, perhaps even a glass of red wine.”

And now, maybe a cup of coffee or two. One way coffee might be working is that it’s known to help the body use insulin. And high insulin has already been proven to increase risk of prostate cancer.

A study, including almost 5,600 men aged 55 years and over randomized to the placebo section of the Prostate Cancer Prevention Trial (PCPT), showed that men whose cholesterol levels were below 200 mg/dL had a 60% decreased risk of Gleason 8 to 10 prostate cancer compared with men who had higher cholesterol levels, researchers reported in Cancer Epidemiology, Biomarkers & Prevention. Clinicians diagnosed prostate cancer in 1,251 men (22%).

The investigators, led by Elizabeth A. Platz, ScD, MPH, of Johns Hopkins Bloomberg School of Public Health in Baltimore, found no association between cholesterol levels and prostate cancer overall.

“Our findings add to the literature supporting a role for cholesterol in the etiology of prostate cancer with a worse prognosis,” the authors wrote.

The PCPT, which started in 1993, investigated whether finasteride could prevent prostate cancer. Researchers randomized subjects to receive 5 mg/day of finasteride or placebo for seven years. The study showed that finasteride treatment was associated with a 25% decreased incidence of prostate cancer.

In contrast to their findings in the placebo arm of the trial, Dr. Platz and her collaborators observed no association between serum cholesterol and high-grade prostate cancer in the finasteride arm. The researchers said the pattern they observed in the placebo arm, in theory, could be explained by a lower sensitivity for detecting high-grade prostate cancer in the men with low rather than high cholesterol, “but this is not the expectation.” Men with low cholesterol, the group explained, on average have a lower prostate volume. Thus a greater proportion of the total prostate could be sampled by needle biopsy, increasing the sensitivity of detecting high-grade tumors. Another explanation, they noted, is that finasteride prevented the same subset of high-grade cancers that low cholesterol would have prevented. It also is possible that the accuracy in detecting high-grade cancers differed in men with low cholesterol in the placebo arm compared with the finasteride arm.

A prostate cancer researcher not involved with the new study, Stephen J. Freedland, MD, of the Duke Prostate Center at Duke University Medical Center in Durham, N.C., said the study by Dr. Platz’s team is consistent with previous research and “provides some of the strongest data to date” linking high cholesterol with an increased risk of high-grade prostate cancer.

Dr. Freedland said he has started to mention this association to men with high cholesterol when counseling them about whether to go for PSA testing. “I say to patients, ‘There are increasing data to suggest that high cholesterol may increase your risk of aggressive prostate cancer.’”

As for whether a man should be placed on a statin to reduce his risk of aggressive prostate cancer, Dr. Freedland observed, “If he has high cholesterol, he should probably be on a statin anyway.” It is unknown whether statin treatment would further reduce the risk in men with low cholesterol, he said.

Previous studies suggest that statin use may protect against advanced prostate cancer. For example, a study published in the Journal of the National Cancer Institute (2006;98:1819-1825) showed that statin use was associated with a 43% decreased risk of advanced prostate cancer and a 65% decreased risk of fatal or metastatic prostate cancer.

Recently, researchers reported on a study involving 1,351 prostate cancer patients who underwent radical prostatectomy (504 who used statins and 847 who did not). Preoperative PSA levels, tumor volume, and percentage of cancer in the surgical specimen were significantly lower in the statin users, who overall had a proportionately lower rate of adverse tumor pathology features, including a significantly reduced risk of positive surgical margins, researchers reported in BJU International (2009; published online ahead of print).

Dr. Freedland—whose research has focused on risk factors for prostate cancer and its recurrence following treatment, as well as on prostate cancer chemoprevention—said it is biologically plausible for cholesterol to be involved in the pathogenesis of high-grade prostate cancer. Cholesterol is the precursor for testosterone, which promotes prostate tumor growth, Dr. Freedland said. Hypothetically, high cholesterol concentrations could mean greater testosterone production, he said. Evidence is mounting that high-grade, castration-resistant tumors can make their own testosterone from cholesterol, he noted.

Cholesterol also may directly stimulate tumor growth, he explained. In addition, all new cells need cholesterol as part of their membranes. “Thus, lower cholesterol means it is harder for the cells to replicate,” he said. “Given that high-grade tumors grow faster, this could explain why low cholesterol only reduced the risk of high-grade disease. All of these mechanisms suggest that it is indeed plausible that high cholesterol could promote more aggressive cancers.”

From the November 2009 Issue of Renal And Urology News

Cholesterol: What Your Doctor Didn’t Tell You

Their findings are only experimental — the stem cells were found in mice — but could explain at least some types of prostate cancer and eventually offer new ways to treat it, they reported on Wednesday in the journal Nature.

The findings also show a potential new source for prostate tumors — so-called luminal cells, which secrete various compounds used in the prostate.

“The role of stem cells in the development of prostate cancer has been a focus of speculation for many years,” Dr. Helen Rippon of Britain’s Prostate Cancer Charity said in a statement.

“Importantly, this new stem cell does not rely on androgens — the male sex hormones that control prostate growth — to survive and grow. This may give a clue as to why prostate cancer often becomes resistant to treatments designed to regulate these androgens in the later stages of the disease,” added Rippon, who was not involved in the research.

“This improved knowledge will also be a step forward in learning how we might help to prevent the disease from developing in men in the first place.”

Michael Shen of Columbia University Medical Center and colleagues named the new stem cells CARNs, for castration-resistant Nkx3.1-expressing cells.

They normally regenerate part of the tissue that lines the inside of the gland, which produces semen. But the cells can also form tumors if certain genes meant to stop out-of-control growth get turned off.

Shen said researchers had believed that tumors arise from a different layer of cells in the prostate, called basal cells.

“Previous research suggested that prostate cancer originates from basal stem cells, and that during cancer formation these cells differentiate into luminal cells,” Shen said in a statement. “Instead, CARNs may represent a luminal origin for prostate cancer.”

After working initially with human cancer cell lines, Ines Diaz-Laviada and colleagues from the University of Alcala in Madrid also tested one compound on mice and discovered it produced a significant reduction in tumor growth. Their research, published in the British Journal of Cancer, underlines the growing interest in the medical use of active chemicals called cannabinoids, which are found in marijuana.

Experts, however, stressed that the research was still exploratory and many more years of testing would be needed to work out how to apply the findings to the treatment of cancer in humans.

“This is interesting research which opens a new avenue to explore potential drug targets but it is at a very early stage,” said Lesley Walker, director of cancer information at Cancer Research UK, which owns the journal. “It absolutely isn’t the case that men might be able to fight prostate cancer by smoking cannabis,” she added

The cannabinoids tested by the Spanish team are thought to work against prostate cancer because they block a receptor, or molecular doorway, on the surface of tumour cells. This stops them from dividing. In effect, the cancer cell receptors can recognize and “talk to” chemicals found in cannabis, said Diaz-Laviada.

“These chemicals can stop the division and growth of prostate cancer cells and could become a target for new research into potential drugs to treat prostate cancer,” she said. Her team’s work with two cannabinoids — called methanandamide and JWH-015 — is the first demonstration that such cannabis chemicals prevent cancer cells from multiplying.

Some drug companies are already exploring the possibilities of cannabinoids in cancer, including British-based cannabis medicine specialist GW Pharmaceuticals. It is collaborating with Japan’s Otsuka on early-stage research into using cannabis extracts to tackle prostate cancer — the most commonly diagnosed cancer in men — as well as breast and brain cancer.

GW has already developed an under-the-tongue spray called Sativex for the relief of some of the symptoms of multiple sclerosis, which it plans to market in Europe with Bayer and Almirall. Other attempts to exploit the cannibinoid system have met with mixed success. Sanofi-Aventis was forced to withdraw its weight-loss drug Acomplia from the market last year because of links to mental disorders.

Cruel Treatment of Medical Marijuana Patient video posted by Sandy Hutchens Cancer Prevention